NCT00304421已完成4 期
Comparison of the Nighttime Effects of Rabeprazole 20 mg to Pantoprazole 40 mg on Standard Meal Stimulated Gastric Acid Secretion and Intragastric pH in H. Pylori Negative Volunteer Subjects With GERD
VA Greater Los Angeles Healthcare System2 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2004年1月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 23
- 试验地点
- 2
- 主要终点
- To test the hypothesis that during the hours 2000 through 0800 following a single dose administration of medication, the median change from baseline values in gastric acid secretion with 20 mg rabeprazole is significantly less than 40 mg pantoprazole
研究概览
简要总结
The purpose of the study is to compare the effect of two different drugs, rabeprazole (20 mg) and pantoprazole (40 mg), and their effects on the amount of acid produced by your stomach on evening and at night after standard protein meal.
详细描述
Gastric acid secretion can be divided into two phases: the daytime phase and the nocturnal phase. Nocturnal acid reflux is presumably more damaging because of loss of salivary neutralization. The present study is designed to measure effects of rabeprazole and pantoprazole on post-prandial and nocturnal gastric acid secretion and intragastric pH in H. pylori-negative volunteers with gastroesophageal reflux disease. These measurement will be used to compare the degree of inhibition of gastric acid secretion between the two drugs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects, 18-65 years of age, inclusive, male or female, of any race, who are willing to undergo testing at the study center.
- •Female subjects must not be able to conceive by reason of surgery, radiation, 2 years past the onset of menopause, or an approved method of contraception (e.g., IUD, oral contraceptives for at least one cycle, implant, or double barrier method). Female subjects of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test before medication is dispensed.
- •Subjects must have a negative result on the screening for H. pylori by serology, and no history of H. pylori eradication.
- •Subjects must have history of GERD with or without antacid use.
- •Subjects must be able to tolerate nasogastric tube placement.
排除标准
- •History of gastric surgery, fundoplication or vagotomy.
- •Pyloric stenosis Barrett's esophagus or esophageal stricture.
- •Treatment with a histamine H2-receptor antagonist, prostaglandin, or sucralfate within 14 days before enrollment into this study.
- •Treatment with rabeprazole, omeprazole, lansoprazole, pantoprazole, esomeprazole, prokinetic agent, or bismuth subsalicylate within 30 days before enrollment into this study.
- •Concurrent serious systemic disorders, including renal insufficiency and hepatic insufficiency.
- •Subjects with neoplasia or undergoing treatment for cancer (e.g., chemotherapy, radiation.
- •Any condition associated with poor subject compliance (e.g., alcohol abuse, drug abuse).
- •History of clinically significant abuse of alcohol defined as (1) patterns of alcohol intake consistent with disruption of normal function in society; (2) history of, or current existence of any indication of difficulty in abstaining from alcohol for the required duration of the present protocol; (3) use of any alcohol within one day of any study period.
- •Subjects who have received any investigational agent within the previous 30 days.
- •Inability of subject to return for scheduled visits.
- •Subjects who, in the opinion of the investigator, are poor medical or psychiatric risks for therapy with an investigational drug.
- •History of any hypersensitivity reaction to rabeprazole, pantoprazole or any of their inactive ingredients.
- •Any significant evidence at screening of endocrine, cardiovascular, and/or pulmonary disorder.
- •Any predisposing condition that might interfere with the absorption, distribution, metabolism, or excretion of drug, or a history of abnormal bleeding tendencies or thrombophlebitis.
- •History of HIV, hepatitis B, or hepatitis C infection.
- •Subjects who are pregnant or likely to become pregnant during the course of this study.
结局指标
主要结局
To test the hypothesis that during the hours 2000 through 0800 following a single dose administration of medication, the median change from baseline values in gastric acid secretion with 20 mg rabeprazole is significantly less than 40 mg pantoprazole
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease PatientsGastroesophageal Reflux DiseaseNCT02135107Eisai Co., Ltd.517
已完成
2 期
A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)HealthyNCT01202071Eisai Co., Ltd.24
已完成
3 期
Open Label Study Evaluating Different Dosing Regimens of Rabeprazole in Gastro-esophageal Reflux Disease (GERD) Patients With Night-time Heartburn Symptoms.HeartburnGastroesophageal RefluxNCT00553449Janssen-Ortho Inc., Canada48
已完成
不适用
Prospective Double-blinded Randomized Controlled Trial of 12-weeks High Dose Rabeprazole (Pariet) in the Treatment of Reflux Laryngitis in Chinese PatientsLaryngitisGastroesophageal RefluxNCT00517114Hospital Authority, Hong Kong200
已完成
3 期
Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)Gastroesophageal Reflux Disease (GERD)NCT00839306Eisai Inc.240